Vertex Pharmaceuticals Incorporated (VRTX)

228.32
1.45 0.64
NASDAQ
Prev Close 226.87
Open 227.30
Day Low/High 225.59 / 230.21
52 Wk Low/High 197.47 / 306.08
Volume 940.19K
Exchange NASDAQ
Shares Outstanding 260.04B
Market Cap 58.95B
P/E Ratio 22.20
Div & Yield N.A. (N.A)
The Next Big Thing in Biotech: Earnings

The Next Big Thing in Biotech: Earnings

Adam Feuerstein, senior columnist for TheStreet, says biotech earnings are the next big thing to watch in biotech.

A Market in Limbo

A Market in Limbo

Traders are jockeying for position as we await the Fed, economic data and key earnings.

The Next Big Thing in Biotech: Dendreon/Vertex Earnings

The Next Big Thing in Biotech: Dendreon/Vertex Earnings

Senior columnist Adam Feuerstein says earnings from Dendreon and Vertex are the next big things in biotech.

The Next Big Thing In Biotech: Vertex

The Next Big Thing In Biotech: Vertex

Adam Feuerstein, Sr. Columnist for TheStreet, says Vertex Pharmaceuticals is the next big thing in biotech.

The 5 Dumbest Things on Wall Street: June 1

The 5 Dumbest Things on Wall Street: June 1

Here is this week's roundup of the dumbest actions on Wall Street.

Slow, but Positive

Slow, but Positive

The longer this action persists, the more anxious folks will be to put idle cash to work.

Biotech Breakout

Biotech Breakout

SPDR S&P Biotech ETF is likely to post new highs in the second quarter.

Daily Recap of the Charts, May 7

Daily Recap of the Charts, May 7

Evan Lazarus of T3Live review the day's market action and sets up your trading plan for the next session.

The Next Big Thing in Biotech: Pfizer

The Next Big Thing in Biotech: Pfizer

Senior columnist Adam Feuerstein says Pfizer is the next big thing in biotech.

Looking for a Blaze of Markups

Looking for a Blaze of Markups

Here are a couple of window-dressing plays as we head into the end of the quarter.

Be Ready for Surprises

Be Ready for Surprises

Earnings season is well upon us, so better to be prepared than, well, taken by surprise.

Divining the Earnings Winners

Divining the Earnings Winners

Based on patterns of estimates revisions, these names might just generate some magic when they report.